A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 works to treat B-ALL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub starszy (dorośli) lub od 2 do 18 lat (dzieci)
- •Rozpoznana białaczka lymphoblastyczna typu B (B-ALL) z więcej niż 5% komórek nowotworowych w szpiku kostnym
- •Białaczka nie reagująca na początkowe leczenie lub ponownie zaatakowana po przerwach w leczeniu
- •Pierwsza wznowa zaraz po wyleczeniu (do 12 miesięcy) lub druga i kolejne wznowy
- •Białaczka Ph-pozytywna leczona wcześniej dwoma lub więcej innymi lekami tyrozynowymi
- •Białaczka powróciła po przeszczepieniu szpiku kostnego
✗ Disqualifies
- •Historia białaczki Burkitta
- •Leczenie innym lekiem anty-CD19 w ciągu ostatnich 3 miesięcy
- •Przeszzczep szpiku kostnego w ciągu ostatnich 12 tygodni
- •Terapia CAR-T w ciągu ostatnich 3 miesięcy
- •Problemy z mózgiem lub opoczą mózgową związane z rakiem
- •Zakażenie HIV lub historia immunodeficjencji
- •Poważne choroby serca lub naczyń krwionośnych
- •Aktywne choroby autoimmunologiczne
Simplified criteria — AI translation
Trial details
- Minimum age
- 2 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
The Second Affiliated Hospital of Third Military Medical University ( Site 0008)
Chongqing, China
Southern Medical University Nanfang Hospital ( Site 0004)
Guangzhou, China
The Second Hospital of Hebei Medical University ( Site 0003)
Shijiazhuang, China
The First Hospital of Harbin ( Site 0005)
Harbin, China
Henan Cancer Hospital-hematology department ( Site 0002)
Zhengzhou, China
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology ( Site 0010)
Wuhan, China
Tongji Hospital affiliated to Tongji Medical College of HUST ( Site 0006)
Wuhan, China
The Affiliated Hospital of Xuzhou Medical University ( Site 0007)
Xuzhou, China
West China Second University Hospital, Sichuan University ( Site 0011)
Chengdu, China
Hematology Hospital of Chinese Academy of Medical Sciences ( Site 0001)
Tianjin, China
The Children's Hospital of Zhejiang University School of Medicine ( Site 0009)
Hangzhou, China
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.